Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Dabrafenib and trametinib,"Melanoma, Resected Stage III with BRAF V600 mutation, Adjuvant treatment",Dabrafenib and trametinib,,Community,
